Physician profile
William Beach
NPI 1205888997
$166,284.95
in general payments reported to CMS, 2019-2025
17 companies · $36K in 2025
The $36K reported for 2025 was more than what 94% of Sports Medicine (Orthopaedic Surgery) providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $6,140 · 2021: $13K · 2022: $70K · 2023: $11K · 2024: $14K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $38K · Consulting Fee: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,400 · Food and Beverage: $1,263 · Travel and Lodging: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $37,620.59 |
| Consulting Fee | $13,200.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,400.00 |
| Food and Beverage | $1,263.48 |
| Travel and Lodging | $908.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $78,537.79 | 2019-2025 | Arthrex |
| Anika Therapeutics, INC. | $59,757.70 | 2022 | |
| Moximed, INC | $13,684.01 | 2024-2025 | Misha Knee System, Small, Left |
| Linvatec Corporation | $9,502.22 | 2019-2025 | Biobrace 23mm, Livatec Knee Preservation System, Linvatec Shoulder Arthroscopy |
| Fortis Surgical, LLC | $2,997.42 | 2019-2025 | |
| Horizon Therapeutics Plc | $519.83 | 2019-2022 | |
| Pacira Therapeutics, INC. | $325.23 | 2019-2021 | |
| Depuy Synthes Sales INC. | $245.69 | 2019-2025 | Monovisc, Orthovisc |
| Arcuro Medical INC | $215.80 | 2022-2024 | Superball |
| Zimmer Biomet Holdings, INC. | $122.85 | 2021 | |
| Aesculap Biologics, LLC | $118.10 | 2019 | |
| Djo, LLC | $110.49 | 2019 | |
| Heron Therapeutics, INC. | $65.74 | 2023 | Zynrelef |
| Ferring Pharmaceuticals INC. | $26.81 | 2021 | |
| Grifols USA, LLC | $22.52 | 2025 | Gamunex-C |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $20.62 | 2023 | Xiaflex |
| Pacira Pharmaceuticals Incorporated | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Beach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.